Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
D000544:Alzheimer Disease / Q000473:pathology*; D001479:Basal Ganglia / Q000473:pathology*; D002540:Cerebral Cortex / Q000473:pathology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D006801:Humans; D009434:Neural Pathways / Q000473:pathology; D009474:Neurons / Q000648:ultrastructure; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010300:Parkinson Disease / Q000473:pathology*; D011950:Receptors, Cholinergic / Q000378:metabolism; D013377:Substantia Innominata / Q000473:pathology*; D013378:Substantia Nigra / Q000473:pathology
D018377:Neurotransmitter Agents; D011950:Receptors, Cholinergic; D002795:Choline O-Acetyltransferase